

Yukio Sonoda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2243328/publications.pdf>

Version: 2024-02-01

85
papers

2,395
citations

257450

24
h-index

233421

45
g-index

87
all docs

87
docs citations

87
times ranked

2724
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. <i>Scientific Reports</i> , 2022, 12, 974.	3.3	8
2	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100940.	0.6	1
3	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	0
4	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100154.	2.1	2
5	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	1.4	9
6	Risk factors for financial toxicity in patients with gynecologic cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 817.e1-817.e9.	1.3	20
7	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 159-164.	2.5	10
8	Safety and Efficacy of Supradiaphragmatic Lymph Node Dissection in Advanced Ovarian Cancer. <i>Journal of Gynecologic Surgery</i> , 2022, 38, 202-206.	0.1	1
9	A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 311-322.	2.2	22
10	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	1.4	2
11	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	1.4	2
12	Diaphragm hernia after debulking surgery in patients with ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100759.	0.6	2
13	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	1.4	14
14	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	1.4	18
15	Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm. <i>Gynecologic Oncology</i> , 2021, 162, 262-267.	1.4	12
16	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. <i>Gynecologic Oncology</i> , 2021, 162, 345-352.	1.4	8
17	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
18	Quaternary and beyond cytoreduction: An updated and expanded analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100851.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. <i>Gynecologic Oncology</i> , 2021, 163, 294-298.	1.4	9
20	The role of imaging in pelvic exenteration for gynecological cancers. <i>British Journal of Radiology</i> , 2021, 94, 20201460.	2.2	4
21	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 222-231.	2.5	2
22	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. <i>Gynecologic Oncology</i> , 2020, 156, 591-597.	1.4	54
23	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	1.4	61
24	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	1.4	16
25	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. <i>Gynecologic Oncology</i> , 2020, 159, 66-71.	1.4	12
26	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1162-1168.	2.5	6
27	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	2.5	29
28	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. <i>Gynecologic Oncology</i> , 2020, 159, 187-194.	1.4	12
29	A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors. <i>Gynecologic Oncology</i> , 2020, 158, 366-374.	1.4	15
30	Surveillance patterns of cervical cancer patients treated with conization alone. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1129-1135.	2.5	3
31	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	1.4	23
32	Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 383-386.	2.5	25
33	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2020, 158, 397-401.	1.4	7
34	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	2.5	7
35	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	2.2	22
36	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1183-1188.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2019, 154, 333-337.	1.4	14
38	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	1.4	24
39	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	1.4	24
40	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
41	Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1377-1380.	2.5	7
42	Is Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients ≥65 Years Old. <i>Annals of Surgical Oncology</i> , 2019, 26, 244-251.	1.5	18
43	Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. <i>Annals of Surgical Oncology</i> , 2018, 25, 984-990.	1.5	12
44	Factors related to teamwork performance and stress of operating room nurses. <i>Journal of Nursing Management</i> , 2018, 26, 66-73.	3.4	49
45	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 461.e1-461.e18.	1.3	22
46	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	1.4	16
47	Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 287-293.	1.4	23
48	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. <i>Gynecologic Oncology</i> , 2018, 150, 44-49.	1.4	30
49	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. <i>Gynecologic Oncology</i> , 2018, 151, 24-31.	1.4	64
50	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	1.4	55
51	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 27-31.	1.4	95
52	Indications for and complications of transfusion and the management of gynecologic malignancies. <i>Gynecologic Oncology</i> , 2017, 146, 416-426.	1.4	18
53	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. <i>Gynecologic Oncology</i> , 2017, 146, 263-267.	1.4	33
54	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 371-374.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 262-266.	1.4	43
56	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 251-256.	1.5	14
57	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	4.1	43
58	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. <i>Gynecologic Oncology</i> , 2016, 142, 13-18.	1.4	2
59	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2016, 23, 2522-2528.	1.5	69
60	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	1.4	12
61	Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. <i>Gynecologic Oncology</i> , 2016, 143, 18-21.	1.4	19
62	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	2.5	16
63	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 217-224.	1.4	42
64	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	1.4	97
65	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2192-2198.	1.5	43
66	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 383-386.	1.4	10
67	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016, 23, 989-993.	1.5	44
68	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 246-251.	1.4	71
69	Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer. <i>Translational Andrology and Urology</i> , 2015, 4, 169-85.	1.4	12
70	Surgical treatment for apparent early stage endometrial cancer. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 1.	1.6	16
71	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. <i>Gynecologic Oncology</i> , 2014, 133, 274-277.	1.4	246
72	Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 299-302.	1.4	14

#	ARTICLE	IF	CITATIONS
73	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 468-472.	1.4	10
74	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014, 134, 455-461.	1.4	180
75	The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. <i>Gynecologic Oncology</i> , 2014, 133, 552-555.	1.4	75
76	Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. <i>Gynecologic Oncology</i> , 2014, 132, 102-106.	1.4	40
77	Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 25-30.	1.4	59
78	Pathologic analysis of ex vivo plasma energy tumor destruction in patients with ovarian or peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1326-30.	2.5	16
79	Fertility-sparing surgery in gynecologic oncology. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 211-221.	0.4	1
80	Schauta radical vaginal hysterectomy. <i>Gynecologic Oncology</i> , 2007, 104, 20-24.	1.4	13
81	Radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy for early-stage cervical cancer in patients who desire to preserve fertility. <i>Gynecologic Oncology</i> , 2007, 104, 50-55.	1.4	13
82	Screening and the prevention of gynecologic cancer: Endometrial cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 363-377.	2.8	55
83	A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?. <i>Gynecologic Oncology</i> , 2004, 95, 534-538.	1.4	143
84	Management of early ovarian cancer. <i>Oncology</i> , 2004, 18, 343-56; discussion 358, 361-2.	0.5	3
85	Optimal therapy and management of endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 37-47.	2.4	7